SEC Form 3 · accession 0001209191-17-067385
Cue Biopharma, Inc. · CUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ronald D. Seidel III
Officer — EVP, Head of R&D
Period of report
Dec 18, 2017
Accepted (ET)
Dec 27, 2017 · 1:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645460
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 445,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $2.86 | holding | — | — | — | — | Sep 7, 2023 | Common Stock | 120,000 | — | D |
Explanation of responses
- F1These Stock Options become exercisable in eight equal semi-annual installments beginning March 7, 2017.